Lupin to attend Kotak, J.P. Morgan investor meets in September

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Lupin will attend the Kotak Healthcare Conference on September 17, 2026
  • The company is also scheduled for a group meet at the J.P. Morgan India Conference on September 21
  • Both events are in-person group meetings with analysts and institutional investors
  • Presentations will follow content already available on exchange websites
powered bylight_fuzz_icon
50414644

*this image is generated using AI for illustrative purposes only.

Lupin will participate in two analyst and investor meetings in September 2026, engaging with the investment community at major financial conferences.

The company disclosed the schedule pursuant to Regulation 30 of the SEBI Listing Regulations, confirming its participation in group meets held in person.

Meeting details

Lupin will engage with analysts and institutional investors at the following events:

Date Event Mode Nature
September 17, 2026 Kotak Healthcare Conference In person Group meet
September 21, 2026 J.P. Morgan India Conference In person Group meet

The company noted that the schedule is subject to change due to exigencies by the company or event organizers. Any presentations made during these events will align with those already available on the company’s website and stock exchanges.

Regulatory disclosure

The disclosure was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited. The registered office of the company is located in Mumbai.

Historical Stock Returns for Lupin

1 Day5 Days1 Month6 Months1 Year5 Years
-0.01%-3.82%-10.95%-10.20%+8.27%+112.68%

What specific strategic updates or financial guidance is Lupin likely to present at the Kotak Healthcare and J.P. Morgan conferences?

How might investor sentiment regarding Lupin's generic drug portfolio shift following these September 2026 engagements?

Are there any pending regulatory approvals or product launches that Lupin may highlight to address current market concerns during these meetings?

Lupin receives US FDA approval for Modafinil Tablets

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Lupin receives US FDA approval for Modafinil Tablets
  • Product is a wakefulness-promoting agent for narcolepsy
  • Approval expands Lupin's portfolio in the US market
powered bylight_fuzz_icon
50071578

*this image is generated using AI for illustrative purposes only.

Lupin has received approval from the US Food and Drug Administration (US FDA) for Modafinil Tablets.

Regulatory approval details

The US FDA nod for Modafinil Tablets represents a regulatory clearance for Lupin to market the product in the United States. Modafinil is a wakefulness-promoting agent commonly prescribed for conditions such as narcolepsy and related sleep disorders.

Parameter Details
Company Lupin
Regulatory body US FDA
Product Modafinil Tablets
Market United States

The approval adds Modafinil Tablets to Lupin's portfolio of US FDA-cleared products, reinforcing the company's presence in the regulated US pharmaceutical market.

Historical Stock Returns for Lupin

1 Day5 Days1 Month6 Months1 Year5 Years
-0.01%-3.82%-10.95%-10.20%+8.27%+112.68%

What is the projected revenue contribution of Modafinil Tablets to Lupin's US portfolio in the next fiscal year?

How will Lupin's pricing strategy for Modafinil Tablets compare to existing competitors in the US wakefulness-promoting agent market?

Does this approval signal an accelerated pipeline for other CNS-related generic drugs currently under review by the FDA?

More News on Lupin

1 Year Returns:+8.27%